Recordati Industria Chimica e Farmaceutica S.p.A.
RCDTFOTCHealthcare● Active
$60.00
+$0.00(+0.00%)
Market Cap$12.2B
P/E Ratio—
52W High$65.44
52W Low$55.88
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RCDTF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.62B | $2.34B | $2.08B | $1.85B | $1.58B |
| Cost of Revenue | $0.83B | $0.74B | $0.60B | $0.57B | $0.43B |
| Gross Profit | $1.79B | $1.60B | $1.48B | $1.29B | $1.15B |
| Gross Margin %(computed) | 68.27% | 68.34% | 71.15% | 69.42% | 72.93% |
| Operating Expenses | |||||
| R&D Expenses | $0.34B | $0.29B | $0.26B | $0.22B | $0.17B |
| G&A Expenses | $0.17B | $0.16B | $0.13B | $0.11B | $0.08B |
| Total Operating Expenses | $1.07B | $0.96B | $0.92B | $0.79B | $0.65B |
| Operating Income | $0.72B | $0.64B | $0.56B | $0.44B | $0.49B |
| Operating Margin %(computed) | 27.49% | 27.28% | 26.80% | 23.60% | 31.02% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.10B | $0.08B | $0.07B | $0.03B | $0.02B |
| Income Before Tax | $0.58B | $0.55B | $0.49B | $0.40B | $0.46B |
| Income Tax Expense | $0.14B | $0.13B | $0.10B | $0.09B | $0.08B |
| Net Income | $0.44B | $0.42B | $0.39B | $0.31B | $0.39B |
| Net Margin %(computed) | 16.94% | 17.79% | 18.69% | 16.85% | 24.43% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.15 | $2.02 | $1.86 | $1.52 | $1.87 |
| Wtd Avg Shares | 0.21B | 0.21B | 0.21B | 0.21B | 0.21B |
| EBITDA | $0.89B | $0.80B | $0.71B | $0.56B | $0.58B |
| EBITDA Margin %(computed) | 33.88% | 33.98% | 34.03% | 30.18% | 36.60% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · EUR · B
Explore more Recordati Industria Chimica e Farmaceutica S.p.A. data
About Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) Income Statement
Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RCDTF reported revenue of $2.62B, gross profit of $1.79B (gross margin 68.27%), and net income of $0.44B — a net profit margin of 16.94%.
Frequently asked questions
RCDTF · 4 questionsRecordati Industria Chimica e Farmaceutica S.p.A. (RCDTF) reported revenue of $2.62B for 2025, up 11.8% year-over-year.
RCDTF revenueRCDTF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09